Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements

被引:0
作者
G. Montrucchio
T. Lupia
D. Lombardo
G. Stroffolini
S. Corcione
F. G. De Rosa
L. Brazzi
机构
[1] University of Turin,Department of Surgical Sciences
[2] Critical Care and Emergency - Città Della Salute E Della Scienza Hospital,Department of Anaesthesia
[3] Cardinal Massaia Hospital,Unit of Infectious Diseases
[4] University of Turin,Department of Medical Sciences
[5] Infectious Diseases,undefined
[6] Città Della Salute E Della Scienza Hospital,undefined
[7] Tufts University School of Medicine,undefined
来源
Annals of Intensive Care | / 11卷
关键词
COVID-19; SARS-CoV-2; CAPA; COVID-19-associated pulmonary aspergillosis; Acute respiratory distress syndrome; Invasive pulmonary aspergillosis;
D O I
暂无
中图分类号
学科分类号
摘要
Invasive pulmonary aspergillosis (IPA) has always been a challenging diagnosis and risk factors an important guide to investigate specific population, especially in Intensive Care Unit. Traditionally recognized risk factors for IPA have been haematological diseases or condition associated with severe immunosuppression, lately completed by chronic conditions (such as obstructive pulmonary disease, liver cirrhosis, chronic kidney disease and diabetes), influenza infection and Intensive Care Unit (ICU) admission. Recently, a new association with SARS-CoV2 infection, named COVID-19-associated pulmonary aspergillosis (CAPA), has been reported worldwide, even if its basic epidemiological characteristics have not been completely established yet. In this narrative review, we aimed to explore the potential risk factors for the development of CAPA and to evaluate whether previous host factors or therapeutic approaches used in the treatment of COVID-19 critically ill patients (such as mechanical ventilation, intensive care management, corticosteroids, broad-spectrum antibiotics, immunomodulatory agents) may impact this new diagnostic category. Reviewing all English-language articles published from December 2019 to December 2020, we identified 21 papers describing risk factors, concerning host comorbidities, ICU management, and COVID-19 therapies. Although limited by the quality of the available literature, data seem to confirm the role of previous host risk factors, especially respiratory diseases. However, the attention is shifting from patients’ related risk factors to factors characterizing the hospital and intensive care course, deeply influenced by specific features of COVID treatment itself. Prolonged invasive or non-invasive respiratory support, as well as the impact of corticosteroids and/or immunobiological therapies seem to play a pivotal role. ICU setting related factors, such as environmental factors, isolation conditions, ventilation systems, building renovation works, and temporal spread with respect to pandemic waves, need to be considered. Large, prospective studies based on new risk factors specific for CAPA are warranted to guide surveillance and decision of when and how to treat this particular population.
引用
收藏
相关论文
共 180 条
[1]  
Schauwvlieghe AFAD(2018)Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Lancet Respir Med 6 782-792
[2]  
Rijnders BJA(2011)Clinical risk factors for invasive aspergillosis Med Mycol 49 7-12
[3]  
Philips N(2012)A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Am J Respir Crit Care Med 186 56-64
[4]  
Baddley JW(2020)Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium Clin Infect Dis 71 1367-1376
[5]  
Blot SI(2012)Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study Intensive Care Med 38 1761-1768
[6]  
Taccone FS(2020)SARS-CoV-2 infection: the role of cytokines in COVID-19 disease Cytokine Growth Factor Rev 54 62-75
[7]  
Van Den Abeele AM(2021)T-helper cell subset response is a determining factor in COVID-19 progression Front Cell Infect Microbiol 11 2620-2629
[8]  
Donnelly Peter J(2020)Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 130 132-143
[9]  
Chen SC(2021)Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis 64 1144-1148
[10]  
Kauffman CA(2020)Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study Clin Infect Dis 63 132-135